Welcome to AntoXa Corporation’s newsroom.
For media inquiries, please contact:
Stacey Curry Gunn
Director of Communications
[email protected]
519.827.1131
See below for links to the latest AntoXa news.
Ron Hosking appointed to AntoXa Corporation Board of Directors
Guelph, Ont., Canada, Nov. 28, 2018 — Ron Hosking, CPA, CA, has been appointed to the AntoXa Corporation Board of Directors, effective immediately. Mr. Hosking is a chartered accountant with three decades of experience as a financial manager in the biotechnology and pharmaceutical industries. He is also Chief Financial Officer ...
AntoXa Corporation granted Defence R&D Canada license for novel, plant-made anti-ricin antibody
GUELPH, Ont., Canada, April 16, 2018— AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale in markets worldwide. The licensing agreement follows work AntoXa and the J.C ...
Study shows antibody’s efficacy against ricin
AntoXa is working with Defence Research & Development Canada (DRDC) to develop and produce a plant-made antibody, PhD9, to protect against ricin exposure, a program that has received more than $400,000 (CDN) from the Government of Canada since 2014. Ricin is a naturally occurring protein from Ricinus communis. It is ...
Studies target immune response to Ebola infection
A University of New Mexico scientist is partnering with AntoXa’s parent company, PlantForm Corporation, to advance research aimed at improving understanding of Ebola virus and improving existing vaccines by inducing more effective immune responses to infection. The project employs PlantForm’s tobacco-plant-based vivoXPRESS® biopharmaceutical manufacturing system. The aim is to express ...
